Where an IRB is concerned with protecting the rights, safety, and welfare of human subjects, an Institutional Biosafety Committee (IBC) is responsible for reviewing projects that involve biologic agents such as recombinant DNA, RNAi, pathogens, and other potentially infectious material, as well as transgenic animals.
An IBC provides recommendations pertaining to the control of biohazards associated with the use of microbiological agents and their vectors. It also represents the interests of the surrounding community with respect to public health and protection of the environment.
All NIH-funded research involving a qualifying biologic agent must have an IBC review. IBC review is considered best-practice even if the project is privately funded.
PrimeIRB has established a strategic partnership with an industry-leading provider in registering and administering IBC reviews. Prime Review Board Services will manage and coordinate the concurrent IRB/IBC review process in compliance with all NIH guidelines.
Want to learn more? Email us.